Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00459173 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Rimonabant as an Aid to Maintenance of Smoking Cessation
A Phase 3 study, sponsored by Sanofi.
- Completed
- Registry status
- Phase 3
- Development phase
- 4,850
- Enrollment target
NCT00459173: Completed Phase 3 study, sponsored by Sanofi.
NCT00459173 is a Phase 3 study that has completed, run by Sanofi. The registered enrollment target is 4,850 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (528% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00459173, a Phase 3 study, has completed, sponsored by Sanofi.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 4,850 participants
- Enrollment target
Study Summary
The primary study objective is to evaluate the efficacy of 2 dose levels of rimonabant (5 mg and 20 mg) for the maintenance of abstinence from smoking. Secondary objectives are to evaluate the effect of rimonabant on craving and weight, the clinical and biological safety of 2 doses of rimonabant rimonabant during a 12-month treatment period and to evaluate the pharmacokinetics of the drug.
Interventions
- DRUG rimonabant (SR141716)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4,850 participants |
| Start Date | 2002-11 |
| Est. Completion | 2005-09 |
| Phase | Phase 3 |
What the finished NCT00459173 record still lists
NCT00459173 is an interventional study that assigns participants to a tested intervention. Its 4,850 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (528% higher).
The record links to 0 conditions, and to 1 intervention - of which rimonabant (SR141716) is the first listed.
NCT00459173 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00459173 about?
NCT00459173 is a clinical study titled "Efficacy and Safety of Rimonabant as an Aid to Maintenance of Smoking Cessation". The primary study objective is to evaluate the efficacy of 2 dose levels of rimonabant (5 mg and 20 mg) for the maintenance of abstinence from smoking. Secondary objectives are to evaluate the effect of rimonabant on craving and weight, the clinical and biological safety of 2 doses of rimonabant ri...
What is the current status of trial NCT00459173?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 4,850 participants. The study started on 2002-11. Estimated completion is 2005-09.
What interventions are being tested in trial NCT00459173?
The interventions under investigation include: rimonabant (SR141716) (DRUG).
Who is sponsoring clinical trial NCT00459173?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00459173's enrollment target sits among peer trials
4,850 53rd of 2000 higher than 1,948 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05252754 · 4,874 participants · Phase 3
Rectal Indomethacin and Oral Tacrolimus Versus Combination to Prevent Post-ERCP Pancreatitis
- NCT05929976 · 4,900 participants
InterNatIonal CHildhood Leukemia Microbiome/MEtabolome Cohort
- NCT01719055 · 4,800 participants
RELIEF - A Global Prospective Observational Post-Market Study to Evaluate Long-Term Effectiveness of Neurostimulation Therapy for Pain
- NCT05485675 · 4,800 participants · NA
Stand & Move at Work II: Effectiveness and Implementation of a Worksite Wellness Program
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia